Description: Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Home Page: www.protagonist-inc.com
PTGX Technical Analysis
7707 Gateway Boulevard
Newark,
CA
94560-1160
United States
Phone:
510 474 0170
Officers
| Name | Title |
|---|---|
| Dr. Dinesh V. Patel Ph.D. | CEO, Pres, Sec. & Director |
| Dr. David Y. Liu Ph.D. | Chief R&D Strategy Officer |
| Dr. Suneel K. Gupta Ph.D. | Chief Devel. Officer |
| Dr. Richard S. Shames | Clinical Advisor |
| Mr. Asif Ali | Exec. VP & Chief Financial Officer |
| Mr. Mohammad Masjedizadeh | Exec. VP & CTO |
| Mr. Matthew M. Gosling | Exec. VP & Gen. Counsel |
| Ms. Carena Spivey | Exec. Director of HR |
| Dr. Ashok Bhandari Ph.D. | Sr. VP of Discovery Chemistry & Process Research |
| Dr. Scott Eric Plevy M.D. | Exec. VP and Therapeutic Head of Gastroenterology |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.9246 |
| Price-to-Sales TTM: | 13.2717 |
| IPO Date: | 2016-08-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 122 |